Thursday, January 07, 2016 7:43:21 AM
QURE
Recent QURE News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:03:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:57:14 AM
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/07/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:14:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:10:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:58:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:54:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:33:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 01:29:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:00:33 PM
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 02/28/2024 12:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:46:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:25:52 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/13/2024 09:33:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 12:12:29 PM
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease • GlobeNewswire Inc. • 12/19/2023 12:05:00 PM
- CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B • PR Newswire (US) • 12/12/2023 12:30:00 AM
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/08/2023 12:05:00 PM
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease • GlobeNewswire Inc. • 11/29/2023 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 11:00:55 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 12:52:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:31:27 PM
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 11/07/2023 12:05:00 PM
- CSL and uniQure Win 2023 Prix Galien USA Award • PR Newswire (US) • 10/27/2023 02:00:00 PM
- Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie B • PR Newswire (Canada) • 10/26/2023 06:38:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM